This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Biotech Stocks to Buy on First Vaccine Approval Optimism
by Zacks Equity Research
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical studies without any disruption.
5 Stocks to Buy at Deep Discount for a Stronger Portfolio
by Nalak Das
Discounted stock price and a favorable Zacks Rank will be the right combination to strengthen one's portfolio in the near future. These stocks include PHM, LEN, SAM, W, DT.
Oil Ends Higher on Vaccine News Despite EIA's Bearish Report
by Nilanjan Choudhury
The top five gainers of the S&P 500 in November were all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Apache (APA), Diamondback Energy (FANG) and TechnipFMC (FTI).
CrowdStrike (CRWD) Beats, Snowflake (SNOW) Mixed in Q3
by Mark Vickery
Cyberintelligence security firm CrowdStrike surged well ahead of estimates on every metric in its Q3 report, while fledgling enterprise software firm Snowflake missed on its bottom line.
Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
After a Historic November, What Awaits ETFs in December?
by Sweta Killa
Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.
Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.
Encouraging News on COVID-19 Vaccine
by Zacks Equity Research
Encouraging News on COVID-19 Vaccine
ADP Reports 307K New Jobs, Revisions Up
by Mark Vickery
307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.
5 International ETFs That Outstripped US Market in November
by Sweta Killa
November was a banner month for the global stock market despite the rising number of COVID-19 cases.
Cimarex Energy (XEC) Up 48.6% QTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid Cimarex (XEC).
Stock Market News for Dec 2, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.
Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
Will Americans Get COVID-19 Vaccine Sooner Than Europeans?
by Kinjel Shah
Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe
Small Cap ETFs Deliver Big Gains for Investors
by Neena Mishra
November was the best month ever for the Russell 2000 index
5 Stocks in Dow ETF That Powered the Best Month Since 1987
by Sweta Killa
Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.
Novavax (NVAX) Rises Despite U.S. Coronavirus Vaccine Study Delay
by Zacks Equity Research
Novavax (NVAX) to begin a phase III study on NVX-CoV2373, its COVID-19 vaccine candidate in the United States and Mexico in the coming weeks. Shares up.
Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment
by Zacks Equity Research
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
Moderna (MRNA) Seeks Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine achieves efficacy rate of 94.1% in primary efficacy analysis. The company files for Emergency Use Authorization to the FDA.
COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap
by Ritujay Ghosh
Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.
Stellar November Paves the Way for a Solid December: 5 Picks
by Tirthankar Chakraborty
Growth-oriented stocks like General Motors (GM), Malibu Boats (MBUU) and LaZBoy (LZB) are likely to do well this month on vaccine optimism and Yellen's possible appointment as US Treasury Secretary.
The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI
Moderna (MRNA) Amends Coronavirus Vaccine Supply Deal in U.K.
by Zacks Equity Research
Moderna (MRNA) amends its present contract with the United Kingdom government to supply two million additional doses of its coronavirus vaccine candidate, mRNA-1273, upon approval.
Stock Market News for Nov 30, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Friday amid optimism surrounding COVID-19 vaccine.